Health Condition 1: F40-F48- Anxiety, dissociative, stress-related, somatoform and other nonpsychotic mental disorders Health Condition 2: null- â?¢ Individual presenting with atleast one of the symptoms like occasional emotional discouragement, occasional /mild Stress/ irritability/ Short temper/Anger and Frustration.
Conditions
Interventions
Intervention1: Emotional discouragement capsules: Emotional discouragement, Each capsule contains Ashvagandha (Withania somnifera root), Brahmi (Bacopa monierii), Shankhapushpi (Convolvulus pluricauli
Sponsors
The Himalaya Drug Company
Eligibility
Inclusion criteria
Inclusion criteria: 1.Male and female subjects with aged between 18-60 years. 2.Individual presenting with atleast one of the symptoms like occasional emotional discouragement, occasional /mild Stress/ irritability/ Short temper/Anger and Frustration. 3.Subjects willing to sign informed consent and follow the study procedure. 4.Has not participated in a similar investigation in the past four weeks.
Exclusion criteria
Exclusion criteria: 1.Those with serious cardiovascular, cerebrovascular, respiratory, liver or renal disease or any other disorder 2.The subjects who have used any drugs, for at least 1 week prior to the study 3.Subjects with a strong history of food or drug allergy of any kind 4.Individuals unwilling to provide informed consent or abide by the requirements of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Clinical improvement in the overall health as assessed by clinical examination of signs and symptoms such as occasional, mild emotional discouragement, mild stress, Frustration and the points mentioned in questionnaire. 2.Restoring levels of Blood levels of DHEA, Cortisol and CRP Timepoint: Subjects will be followed up and the clinical assessment will be done on the following visit days: Visit 0- At entry visit, baseline Visit 1- At the end of 2nd week Visit 2- At the end of 4th week Visit 3- At the end of 6th week (End of the study). | — |
Secondary
| Measure | Time frame |
|---|---|
| Compliance of the subject to the drug treatment and the incidence of events.Timepoint: Subjects will be followed up and the clinical assessment will be done on the following visit days: Visit 0- At entry visit, baseline Visit 1- At the end of 2nd week Visit 2- At the end of 4th week Visit 3- At the end of 6th week (End of the study). | — |
Countries
India
Contacts
Public ContactDr Palaniyamma
The Himalaya Drug Company
Outcome results
None listed